Diabetes Advocates Call For National Strategy, Leadership to Reduce Diabetes and Advance Detection and...( About Diabetes Known as the ...),Health

About Diabetes

Known as the "silent killer," diabetes is the fifth-deadliest disease in the U.S. In addition to its effects on the nation's health, diabetes also takes a toll on the economy. The direct and indirect economic costs for diagnosed diabetes, undiagnosed diabetes, pre-diabetes and gestational diabetes in 2007 were an estimated $218 billion, according to a recent Lewin Group study commissioned by NCDP. In 2005, the federal government spent nearly $80 billion on diabetes treatment, with only $4 billion of this amount invested in prevention and health promotion.

Nearly 24 million Americans have diabetes and another 57 million have pre-diabetes. Research shows that a child born after the year 2000 has a one in three chance of developing diabetes, and minority children have a one in two chance of developing diabetes.

About the National Changing Diabetes((R)) Program

The National Changing Diabetes((R)) Program (NCDP) is a multi-faceted initiative that brings together leaders in diabetes and policy to improve the lives of people with diabetes. NCDP strives to create change in the U.S. health care system to provide dramatic improvement in the prevention and care of diabetes. Launched in 2005, NCDP is a program of Novo Nordisk. For more information, please visit www.ncdp.com.

About Novo Nordisk

Novo Nordisk is a healthcare company with an 86-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by
'/>"/>